Umeå University's logo

umu.sePublications
Planned maintenance
A system upgrade is planned for 17/11-2026, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Dosing and discontinuation of methylphenidate medication in relation to weight status in children and adolescents
Unit of Clinical Pharmacology, Department of Pharmaceuticals, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Swedish Medical Products Agency, Uppsala, Sweden; Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.
Bioinformatics and Data Centre, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden; The NEPI foundation-Network for Pharmacoepidemiology, Stockholm, Sweden.
Show others and affiliations
2026 (English)In: Pediatric Drugs, ISSN 1174-5878, E-ISSN 1179-2019, Vol. 28, no 1, p. 89-100Article in journal (Refereed) Published
Abstract [en]

Background and Objective: Evidence and clinical guidelines on methylphenidate dosing in different weight status groups are limited. This study aimed to evaluate real-world methylphenidate dosing practices and treatment discontinuation rates in children and adolescents in relation to weight status.

Method: We used data from the BMI Epidemiology Study Gothenburg cohort, which includes weight and height measurements linked to national registers. Exposures included body weight, standardised body mass index (zBMI), and body mass index (BMI) status. The main outcome was the dose and weight-adjusted dose of methylphenidate for the baseline and follow-up prescriptions. We used a logistic regression model to evaluate treatment discontinuation in relation to weight status, sex, and age.

Results: The study included 1741 children and adolescents who initiated methylphenidate treatment and had BMI available. Among them, 612 had a follow-up prescription with BMI available. Children and adolescents with overweight and obesity received slightly higher absolute doses of methylphenidate at baseline prescriptions, but lower weight-adjusted doses. Children and adolescents with underweight received higher weight-adjusted doses. Absolute dose increases between treatment initiation and follow-up were highest in children and adolescents with obesity and lowest in children and adolescents with underweight. Girls received higher absolute and weight-adjusted doses than boys at follow-up, while children over 12 years of age received higher absolute but lower weight-adjusted doses than children under 12 years. A significantly higher proportion of children and adolescents with baseline underweight discontinued treatment during the first year, compared with the normal weight group. Beside lower baseline zBMI, female sex and higher age were also significantly associated with treatment discontinuation during the first year.

Conclusion: Our findings suggest that weight status, sex, and age are significantly associated with differential methylphenidate dosing and treatment discontinuation in children and adolescents.

Place, publisher, year, edition, pages
Adis , 2026. Vol. 28, no 1, p. 89-100
National Category
Pediatrics
Identifiers
URN: urn:nbn:se:umu:diva-246669DOI: 10.1007/s40272-025-00728-zISI: 001608030400001PubMedID: 41191299Scopus ID: 2-s2.0-105021118690OAI: oai:DiVA.org:umu-246669DiVA, id: diva2:2015413
Funder
Swedish Research Council, 2021-01439Swedish Heart Lung Foundation, 20220620Swedish Heart Lung Foundation, 20220406Available from: 2025-11-21 Created: 2025-11-21 Last updated: 2026-03-18Bibliographically approved

Open Access in DiVA

fulltext(1082 kB)19 downloads
File information
File name FULLTEXT02.pdfFile size 1082 kBChecksum SHA-512
144f5bb01c292801688fea14978d92ebe4ae07080b2ee0d619d4a14920c62b49e82bea9f8683b3edfe2ce513c985daad4f53f9fc58351605e1239feb15ef9217
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Halldner, Linda

Search in DiVA

By author/editor
Halldner, Linda
By organisation
Child and Adolescent Psychiatry
In the same journal
Pediatric Drugs
Pediatrics

Search outside of DiVA

GoogleGoogle Scholar
Total: 88 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 318 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf